In the news: Tool may help predict risk of breast cancer recurrence
Feb. 11, 2025
The MeCo Score tool may help to identify people with early HER2-negative breast cancer who are most likely to benefit from treatment that seems to reduce recurrence risk.
Image
If the tissue of early-stage HER2-negative breast cancer becomes thick and stiff — a process called fibrosis by doctors — it can cause the cancer to come back (recur) in parts of the body away from the breast (metastasis). A small study suggests that an experimental tool called the MeCo Score may be able to identify people with HER2-negative breast cancer that are most likely to benefit from taking medicine for fibrosis to reduce recurrence risk. The results were published in Clinical Cancer Research.